Experimental TB vaccine a ‘game changer’ that offers new hope
Finding new ways to combat TB is particularly important for SA, where the HIV epidemic has fuelled the spread of the infectious disease
31 October 2019 - 19:40
An experimental tuberculosis (TB) vaccine developed by GlaxoSmithKline (GSK) protects half the people who received it, scientists announced at the 50th union world conference on lung health earlier this week, offering fresh hope in the fight against the deadly disease.
Finding new ways to combat TB is particularly important for SA, where the HIV epidemic has fuelled the spread of the infectious disease. In 2018, SA had 301,000 new TB cases, and the disease killed an estimated 63,000 people, according to the World Health Organisation. Millions more South Africans have dormant, or latent, TB...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.